GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » 6-1 Month Momentum %

Nymox Pharmaceutical (Nymox Pharmaceutical) 6-1 Month Momentum % : -55.61% (As of May. 09, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-09), Nymox Pharmaceutical's 6-1 Month Momentum % is -55.61%.

The industry rank for Nymox Pharmaceutical's 6-1 Month Momentum % or its related term are showing as below:

NYMXF's 6-1 Month Momentum % is ranked worse than
90.6% of 1522 companies
in the Biotechnology industry
Industry Median: 0.215 vs NYMXF: -55.61

Competitive Comparison of Nymox Pharmaceutical's 6-1 Month Momentum %

For the Biotechnology subindustry, Nymox Pharmaceutical's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's 6-1 Month Momentum % falls into.



Nymox Pharmaceutical  (OTCPK:NYMXF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Nymox Pharmaceutical 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

NYMOX Update

By Marketwired 07-07-2023

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022

NYMOX Provides Shareholder Update

By Marketwired Marketwired 09-10-2021